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Diabetes Mellitus in Older Adults: Underdiagnosis and 
Undertreatment 
you are interested in type 2 diabetes mellitus, one of the 
older adults, this is the best of times and the worst of times. 
First, the good news. A growing body of evidence provides a 
stronger framework for understanding the scope of this con- 
dition, its impact on the lives of older people, and the poten- 
tial for substantially improved therapeutic outcomes. The 
1997 report of the American Diabetes Association's Expert 
Committee' summarizes some of these advances, proposes 
new diagnostic criteria that have been widely adopted (but 
see more about this below), and recommends screening for 
diabetes on a regular basis in all older adults. Intervention 
studies such as the United Kingdom Prospective Diabetes 
Study and various lipid-lowering trials have demonstrated 
that rates of both the microvascular and macrovascular ad- 
verse outcomes of type 2 diabetes can be al- 
though much of this data requires extrapolation from 
middle-aged to older-aged populations. Thus, people with 
diabetes mellitus may particularly benefit from aggressive 
identification and treatment of hypertension and lipid disor- 
ders. A diagnosis of diabetes mellitus puts an individual in the 
highest risk group in the current classification from the NIH 
Joint National Committee on High Blood Pressure and sets 
an aggressive target of less than 130/85 for blood pressure 
control in such individuals.' Based on their high risk for 
cardiovascular disease,6 lowering the target LDL cholesterol 
goal for people with a diagnosis of diabetes mellitus to less 
than 100 mg/dL, regardless of the presence of documented 
coronary heart disease, is being advocated and may be 
adopted as an official recommendation. 
The impact of glucose lowering on outcomes is still 
somewhat controversial, although there now seems little 
doubt that aggressive lowering of glucose levels will reduce 
the rate of microvascular complications of diabetes mellitus. 
Interventions for specific diabetes complications such as ret- 
inopathy and nephropathy have demonstrated efficacy. A 
growing list of highly effective therapeutic agents are avail- 
able to treat hypertension and hyperlipidemia in people with 
diabetes. Furthermore there is now a rapidly growing list of 
options for treatment of hyperglycemia with agents available 
to address a variety of contributory mechanisms such as 
impaired insulin secretion, increased hepatic glucose produc- 
tion, and impaired insulin-mediated glucose uptake, as well 
as interfering with gastrointestinal absorption of glucose. The 
opportunities for combination therapy, given different modes 
of action of various agents, are expanding greatly. 
Although this could be the best of times for diagnosis and 
treatment of diabetes mellitus in older adults, many serious 
challenges confront us. The new ADA diagnostic criteria 
focus on fasting serum glucose, a relatively easy test to use for 
If leading causes of increased morbidity and mortality in screening, and downplay the use of glucose tolerance testing. The ADA's Expert Committee recognized that focusing on 
the fasting serum glucose will lead to underdiagnosis, missing 
individuals who have marked hyperglycemia after glucose 
challenge, so called isolated postchallenge hyperglycemia. 
However, they may not have realized that isolated postchal- 
lenge hy erglycemia is particularly common among older 
adults,'3'Thus, the new ADA criteria and focus on the fasting 
glucose level will lead to underdiagnosis of type 2 diabetes 
mellitus particularly in older adult populations. Unfortu- 
nately, older individuals with isolated postchallenge hyper- 
glycemia seem to have an increased risk for cardiovascular 
disease equal to those with overt fasting hypergly~emia.~-" 
However, this is only part of the problem of underdiagnosis. 
Epidemiologic studies suggest that 30 to 50% of people who 
meet criteria for diabetes mellitus in the United States (even 
using conservative 1997 ADA criteria), do not know that 
they have diabetes.' This is not surprising as there are also 
many older people with undiagnosed hypertension, hyperlip- 
idemia, and other disorders. Even worse, despite the many 
advances in therapeutics, the overall population success in 
treatment of these important risk factors has been disap- 
pointing. Targets for hypertension, hyperlipidemia, and hy- 
perglycemia are often not The paper by Shorr 
et al. in this issue of the Journal of the American Geriatrics 
S ~ c i e t y ' ~  confirms and extends previous studies reporting 
lack of adequate control of hyperglycemia in many older 
 adult^.'^.^^ We can take little solace in the finding that the 
percentage of older people with poor control may be slightly 
less than in other age groups, although this is an interesting 
finding that merits further investigation. It could represent a 
survival effect, with disproportionate early death of those 
with the poorest diabetes control, or it could possibly reflect 
a somewhat earlier diagnosis or responsiveness to treatment 
of some older people. 
See also p 264 
~ ~ ~ ~~ ~ 
The causes of the troublesome gap between what we 
know and what we are able to deliver successfully to patients 
are uncertain and are likely multifactorial. It is hard to believe 
that lack of physician knowledge is important given the 
barrage of publicity and educational efforts addressing man- 
agement and targets for hypertension, hyperlipidemia, and 
diabetes mellitus. But can a physician adequately present 
information to patients and provide needed therapeutic ad- 
justments in a 15-minute office visit? Undoubtedly, we need 
to come up with better and more efficient ways of providing 
education and follow-up to patients so that there is greater 
motivation for adherence to sometimes complex diabetes 
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interventions.16 For a patient with diabetes alone, in addition 
to a diet prescription and exercise recommendation, thera- 
peutic guidelines might lead to multiple drug regimens for 
hyperglycemia and blood pressure control as well as an 
additional drug for hyperlipidemia. Other drugs would be 
indicated for individuals with evidence of diabetes complica- 
tions such as nephropathy, existing coronary disease, etc. 
Tasks often presented as simple, such as use of a blood 
glucose monitor, are, in fact, very ~omplex . '~  Surely the 
dramatic advances occurring in information technology can 
help us deal with this complexity and do a better job of 
translating the growing body of medical knowledge into 
improved outcomes for our older patients with type 2 diabe- 
tes mellitus. 
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